B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium Injections into the U.S. market, expanding its portfolio to include 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL). These launches expand B. Braun's portfolio to become the largest offering of Heparin Premixed bags in the U.S. market. The 250 mL and 500 mL bags will feature a 2D enhanced barcode. The 2D enhanced barcode design includes the National Drug Code (NDC) number, lot number and expiration date, along with increased spacing between the two 1D barcodes. These enhancements are designed to help improve the accuracy and efficiency of barcode scanning.
The B. Braun Heparin portfolio is manufactured using EXCEL IV Containers, which are not made with DEHP, PVC or natural rubber latex, prioritizing patient and environmental safety. The product is produced and distributed from B. Braun's Irvine, California pharmaceutical manufacturing facility.
"Expanding our Heparin Sodium Injection portfolio underscores our commitment to healthcare providers and their patients. By offering the largest selection of premixed Heparin products in the market, we are helping to provide healthcare workers with the tools they need to deliver precise and effective care," said Shawn Brinson, Director of Marketing, Injectable Drugs, B. Braun Medical Inc.
Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL), are indicated as anticoagulants to maintain catheter patency.
